Streetbeat News

Regulatory

PKX

South Korea has banned short selling through the first half of 2024, leading to a rise in the shares of POSCO Holdings.

Portfolio Pulse from Luke J Jacobi

November 06, 2023 | 1:06 pm

BLTE

Belite Bio has presented the final data from a 24-month, Phase 2 study of Tinlarebant in childhood-onset Stargardt disease at the American Association of Ophthalmology Annual Meeting.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 1:05 pm

AMKR

AMZN

CIEN

WMT

Insiders at four major companies, Amazon (AMZN), Walmart (WMT), Ciena Corporation (CIEN), and Amkor Technology (AMKR), have recently sold shares. The reasons for these sales vary, with Ciena reporting positive Q3 results, Amkor showing a YoY decrease in Q3 EPS results and issuing Q4 revenue guidance below estimates, Walmart planning to open a new fulfillment center, and Amazon facing allegations from the FTC.

Portfolio Pulse from Lisa Levin

November 06, 2023 | 12:44 pm

FREY

FREYR Battery has announced an extraordinary general meeting of shareholders on December 15, 2023, to discuss the previously announced process to redomicile from Luxembourg to the U.S.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:31 pm

ZVSA

ZyVersa Therapeutics has published an article in a peer-reviewed journal demonstrating that inhibiting NLRP3 inflammasomes can reduce kidney damage and dysfunction associated with PM2.5 pollutant. The company's stock symbol is ZVSA.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:11 pm

CABA

Cabaletta Bio has received FDA clearance for its Investigational New Drug (IND) application for CABA-201, a treatment for generalized myasthenia gravis.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 12:03 pm

NRXP

NRx Pharmaceuticals and Nephron Pharmaceuticals have signed an agreement to manufacture a version of Ketamine for treating suicidal depression. The partners aim to submit a New Drug Application by March 1, 2024, and target a finished drug with two-year shelf stability for November 2024, pending FDA approval.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:55 am

CLDX

Celldex Therapeutics has announced positive topline results from its Phase 2 trial of Barzolvolimab for moderate to severe chronic spontaneous urticaria refractory to antihistamines. The trial met its primary endpoint, showing a decrease in disease activity across multiple doses.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:43 am

KPRX

Kiora Pharmaceuticals has announced positive topline results from its Phase 1/2 trial, demonstrating that KIO-301 has the potential to significantly improve vision in patients with retinitis pigmentosa who have ultra-low vision or complete blindness.

Portfolio Pulse from Benzinga Newsdesk

November 06, 2023 | 11:18 am

TSLA

Due to actions taken by Elon Musk, over 100 studies about X have been canceled, suspended, or changed, as reported by Reuters. This is because Musk's actions have limited access to necessary information. Tesla (TSLA) may be indirectly affected by this news.

Portfolio Pulse from Charles Gross

November 06, 2023 | 11:15 am